Home > Insider Trading > Filing (0000899243-20-017498)

Filing Details

Accession Number:: 0000899243-20-017498
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-23 17:41:00
Reporting Period:: 2020-06-19

Accepted Time:: 2020-06-23 17:41:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1281933	K Douglas Bratton	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723783	Bratton Capital Inc.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723787	Bratton Capital Management, L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723842	Neuro Line Partners Lp	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-06-19	82,481	$24.20	870,554	No	4	S	Indirect	By Neuro Line Partners, L.P.
Common Stock	Disposition	2020-06-19	62,439	$25.00	808,115	No	4	S	Indirect	By Neuro Line Partners, L.P.
Common Stock	Disposition	2020-06-22	65,373	$24.66	742,742	No	4	S	Indirect	By Neuro Line Partners, L.P.
Common Stock	Disposition	2020-06-22	24,683	$25.12	718,059	No	4	S	Indirect	By Neuro Line Partners, L.P.
Common Stock	Disposition	2020-06-23	16,777	$25.69	701,282	No	4	S	Indirect	By Neuro Line Partners, L.P.
Common Stock	Disposition	2020-06-23	3,247	$26.19	698,035	No	4	S	Indirect	By Neuro Line Partners, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Neuro Line Partners, L.P.
No	4	S	Indirect	By Neuro Line Partners, L.P.
No	4	S	Indirect	By Neuro Line Partners, L.P.
No	4	S	Indirect	By Neuro Line Partners, L.P.
No	4	S	Indirect	By Neuro Line Partners, L.P.
No	4	S	Indirect	By Neuro Line Partners, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,644,881	Indirect	By AKDL, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.60, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7) and (8).
These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.
(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.94 to $24.93, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.94 to $25.34, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.09 to $26.085, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.105 to $26.32, inclusive.
These shares of common stock of the Issuer are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.
(Continued from Footnote 7) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.